Merck Begins Phase 3 Trial of Ohtuvayre for COPD Exacerbations
Merck has initiated the Enhance-3 phase 3 trial evaluating Ohtuvayre in chronic obstructive pulmonary disease exacerbations.
Merck has initiated the Enhance-3 phase 3 trial evaluating Ohtuvayre in chronic obstructive pulmonary disease exacerbations.